The Latest Research Progress of IER3 in Clinical Significance and Mechanisms: Hepatocellular Carcinoma and Other Malignant Tumors
Clinical Medicine and Pharmacology · 2025
DOI: 10.70731/smem5v44 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Medicine and Pharmacology, 2025. Verfasst von Wenbing Li und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Malignant tumor is one of the diseases threatening human health, and liver cancer is the most common. Hepatocellular carcinoma (HCC) is the most common clinicopathological subtype. Immediate early response 3 (IER3) plays a regulatory role in a variety of malignant tumors. This article reviews the latest research progress on the clinical significance and mechanism of IER3 in HCC and a variety of malignant tumors.
Zitieren
APA
Li, W., Zhang, X., Yang, Y., Zhou, Z., Huang, Z., & Li, H. (2025). The Latest Research Progress of IER3 in Clinical Significance and Mechanisms: Hepatocellular Carcinoma and Other Malignant Tumors. Clinical Medicine and Pharmacology. https://doi.org/10.70731/smem5v44
Vancouver
Li W, Zhang X, Yang Y, Zhou Z, Huang Z, Li H. The Latest Research Progress of IER3 in Clinical Significance and Mechanisms: Hepatocellular Carcinoma and Other Malignant Tumors. Clinical Medicine and Pharmacology. 2025. doi:10.70731/smem5v44
BibTeX
@article{Li2025,
author = {Li, Wenbing and Zhang, Xinlong and Yang, Yanting and Zhou, Zenghua and Huang, Zhenbo and Li, Hui},
title = {The Latest Research Progress of IER3 in Clinical Significance and Mechanisms: Hepatocellular Carcinoma and Other Malignant Tumors},
journal = {Clinical Medicine and Pharmacology},
year = {2025},
doi = {10.70731/smem5v44}
}
EUVIMED